AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14653226
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg quazepam administered 2 hours after a meal
Trial: 8873541
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 1.37 ng/ml
Trial: 8873541
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 32 ng/ml
Trial: 8873541
Drug: Isoflurane alone
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane alone (0 ng/ml remifentanil)
Trial: 3132055
Drug: Nalbuphine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.2 mg/kg and midazolam 0.05 mg/kg
Trial: 3132055
Drug: Midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.05 mg/kg alone
Trial: 21337043
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) - two injections of 1.25 mg IVB 6 weeks apart
Trial: 12612157
Drug: TOP/beta-glucan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOP/beta-glucan treatment (1.8 g TOP and 2.8 g beta-glucan/d)
Trial: 12612157
Drug: Control foods
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control foods (similar to treatment but without TOP and beta-glucan)
Trial: 12612157
Drug: TOP/beta-glucan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOP/beta-glucan treatment
Trial: 7313578
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) administration of ampicillin
Trial: 7313578
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of ampicillin
Trial: 7313578
Drug: Both IM
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both IM and IV administration of ampicillin
Trial: 19489429
Drug: Individual reminiscence
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual reminiscence therapy (5-6 weekly sessions, 30-60 minutes each)
Trial: 15483468
Drug: Recombinant gp120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant gp120 HIV vaccine (AIDSVAX B/B)
Trial: 11213870
Drug: Abalon (soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abalon (soy protein [50 g/day] with high levels of isoflavones [minimum 165 mg/day] and cotyledon fiber [20 g/day])
Trial: 11213870
Drug: Placebo (casein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (casein [50 g/day] and cellulose [20 g/day])
Trial: 2802549
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (1,000 mg single dose)
Trial: 2802549
Drug: Cefaclor (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (250 mg three times a day for 7 days)
Trial: 28381506
Drug: IV immunoglobulin
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV immunoglobulin (IVIg) administered IV at doses of 0.2 or 0.4 g/kg every 2 weeks for 18 months
Trial: 28381506
Drug: Placebo (low‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (low‐dose albumin)
Trial: 19366272
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg/day (with option to adjust to 5 or 10 mg/day at weeks 4 and 8)
Trial: 19366272
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER 4 mg/day (pre-washout)
Trial: 19366272
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug (post-washout)
Trial: 9069297
Drug: Sucralfate plus
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate plus antacid, diphenhydramine, and viscous lidocaine
Trial: 9069297
Drug: Standard combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combination of antacid, diphenhydramine, and viscous lidocaine
Trial: 8366411
Drug: Amoxicillin/clavulanate potassium
RxNorm normalized name: Amoxicillin/Clavulanate Potassium 250 MG-125 MG Oral Tablet
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate potassium for 10 days
Trial: 30010081
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic fields (PEMFs) treatment (50 min/session, 6 sessions/week, total of 25 sessions)
Trial: 25092690
Drug: Nemonoxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin (250 to 750 mg)
Trial: 25092690
Drug: Nemonoxacin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin (maximum dose 1,250 mg)
Trial: 18478914
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy + NPPV
Trial: 9591438
Drug: Eosinophil cationic
RxNorm normalized name: Eosinophil cationic protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eosinophil cationic protein (ECP) evaluation before, during, and after immunotherapy with pollen or mite allergens (Allergovit or Novo‐Helisen, Nexter, Allergopharma)
Trial: 9591438
Drug: ECP levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECP levels during immunotherapy
Trial: 7887824
Drug: 2-hour hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour hemodialysis at high blood flow (400 ml/min)
Trial: 7887824
Drug: 4-hour hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-hour hemodialysis at low blood flow (200 ml/min)
Trial: 3348136
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) sublingual tablets
Trial: 28678044
Drug: Screening for
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening for gastrointestinal risk factors and prophylactic proton pump inhibitor (PPI) therapy (pantoprazole 40 mg for 1 year)
Trial: 28678044
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no screening or PPI therapy)
Trial: 26431854
Drug: TII SCB
RxNorm normalized name: SCB-2019
DrugBank: SCB-2019 (DB15805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TII SCB (16 mL of lidocaine 1.5% with epinephrine 5 µg·mL(‐1) into the largest neural cluster and additional 16 mL divided into equal aliquots injected inside each satellite cluster)
Trial: 26431854
Drug: AXB (5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXB (5.5 mL around the musculocutaneous nerve and 23.5 mL at the 6 o'clock position of the axillary artery)
Trial: 23719518
Drug: Nontherapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontherapeutic dose of intermittent ultrasound on the affected side
Trial: 17630036
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin)
Trial: 17630036
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (capecitabine, irinotecan, and capecitabine plus oxaliplatin)
Trial: 15450049
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) oral suspension 800 mg/d for 12 weeks
Trial: 9715363
Drug: Clomipramine (open
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (open maintenance treatment)
Trial: 8071282
Drug: Dothiepin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dothiepin (150 mg nightly)
Trial: 8071282
Drug: Doxepin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (150 mg nightly)
Trial: 786358
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose of phenytoin sodium at 12.00 hours
Trial: 786358
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or three spaced doses of phenytoin sodium/day
Trial: 28551844
Drug: Minocycline 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 200 mg on day 1 followed by 100 mg twice daily
Trial: 21967830
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physician and group incentives
Trial: 19757980
Drug: Acupressure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure therapy (AT)
Trial: 17694378
Drug: Combined intraarterial
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intraarterial and intramuscular transplantation of autologous mononuclear bone marrow stem cells
Trial: 15093755
Drug: Dihydropyridine calcium
RxNorm normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydropyridine calcium channel antagonists (nifedipine or nicardipine)
Trial: 11367652
Drug: Tripterygium Wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium Wilfordii Complex Ester Tablet (TWT), 2 tablets, 3 times a day for 6 weeks
Trial: 11367652
Drug: Tripterygium Wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium Wilfordii Polycoside Tablet (TPT), 2 tablets, 3 times a day for 6 weeks
Trial: 11367652
Drug: Tripterygium Wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium Wilfordii Complex Ester Tablet (TWT)
Trial: 11367652
Drug: Tripterygium Wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium Wilfordii Polycoside Tablet (TPT)
Trial: 7889947
Drug: Teicoplanin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (400 mg single intravenous dose)
Trial: 7889947
Drug: Cefamandole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (2 g before and 1 g after surgery)
Trial: 26847031
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support group attendance (8 weekly sessions of 2 hours each)
Trial: 19274316
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg (1 ml) of morphine diluted in 9 ml of saline
Trial: 19274316
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg (10 ml) of 0.25% bupivacaine without epinephrine
Trial: 8882904
Drug: V0.1-rest in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V0.1-rest in normal subjects (Nor: 0.25 +/- 0.10 l/s), CPE (0.27 +/- 0.06 l/s), IP (0.26 +/- 0.06 l/s)
Trial: 8882904
Drug: V0.1-max in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V0.1-max in normal subjects (Nor: 3.66 +/- 1.16 l/s), CPE (0.82 +/- 0.25 l/s), IP (1.02 +/- 0.21 l/s)
Trial: 3884032
Drug: Conventional superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional superficial X-ray therapy (300 rad, 3 Gy)
Trial: 3884032
Drug: Grenz ray
RxNorm normalized name: Ray Dol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grenz ray therapy (900 rad, 9 Gy)
Trial: 22017365
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with house dust mite extract for 2 years
Trial: 22017365
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) and Placebo
Trial: 20636999
Drug: Cream B
RxNorm normalized name: Cream Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream B (cosmetic emulsion with active ingredients: soy and jasmine)
Trial: 20636999
Drug: Cream A
RxNorm normalized name: KIT, CREAM AND GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream A (vehicle without active ingredients)
Trial: 18569241
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of computer programs and teacher-led presentation
Trial: 16055571
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (weekly relaxation and focus group discussions)
Trial: 12448352
Drug: Inhaled capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled capsaicin (0.4 mumol/L)
Trial: 12448352
Drug: Inhaled capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled capsaicin (2 mumol/L)
Trial: 12448352
Drug: Inhaled capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled capsaicin (10 mumol/L)
Trial: 10598433
Drug: Intraarticular morphine/bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular morphine/bupivacaine (25 ml of 0.25% bupivacaine and 2 mg of morphine)
Trial: 10598433
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diclofenac i.m. (75 mg) and intraarticular morphine/bupivacaine
Trial: 10598433
Drug: Diclofenac i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac i.m. (75 mg)
Trial: 1752623
Drug: Twice a
RxNorm normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice a day long acting sustained release isosorbide dinitrate (SRISDN)
Trial: 1752623
Drug: Four times
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times daily short acting isosorbide dinitrate
Trial: 7091638
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg domperidone
Trial: 7091638
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic antiemetic medication (control group)
Trial: 27875287
Drug: Standard-dose AAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose AAs (2.4 g/[kg·d]) and SOY (n = 24)
Trial: 27875287
Drug: Standard-dose AAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose AAs (2.4 g/[kg·d]) and MIX (n = 25)
Trial: 27875287
Drug: High-dose AAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose AAs (3.6 g/[kg·d]) and SOY (n = 24)
Trial: 27875287
Drug: High-dose AAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose AAs (3.6 g/[kg·d]) and MIX (n = 23)
Trial: 17494885
Drug: Uptitration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uptitration of benazepril (median 20 mg/d; range 10 to 40)
Trial: 17494885
Drug: Uptitration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uptitration of losartan (median 100 mg/d; range 50 to 200)
Trial: 17494885
Drug: Conventional dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosage of benazepril (10 mg/d)
Trial: 17494885
Drug: Conventional dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosage of losartan (50 mg/d)
Trial: 11804989
Drug: Nicorandil (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (an agonist of K(ATP) channels)
Trial: 11804989
Drug: Glibenclamide (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (an antagonist of K(ATP) channels)
Trial: 103358
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg x 3-4 per day, starting 1-2 days before menstruation
Trial: 103358
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg x 3-4 per day, starting on the first day of bleeding
Trial: 31959202
Drug: BCAA-based supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA-based supplement (13.2g carbohydrates; 3.2g BCAA; 1.6g L-alanine per dose)
Trial: 31959202
Drug: BCAA-based supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA-based supplement
Trial: 24989842
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D treatment (14,000 units once weekly for 6 weeks)
Trial: 22164761
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day Lentinex for 6 weeks
Trial: 22164761
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day Lentinex
Trial: 19673020
Drug: Split dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose midazolam in combination with meperidine (Group A)
Trial: 19673020
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose midazolam in combination with meperidine (Group B)
Trial: 16771948
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose pegylated interferon alpha-2b (50 micrograms or 100/150 micrograms based on weight) + 1000 mg ribavirin daily for 48 weeks
Trial: 16771948
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose pegylated interferon alpha-2b (50 micrograms or 100/150 micrograms based on weight) + 1000 mg ribavirin daily for 48 weeks
Trial: 16771948
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose pegylated interferon alpha-2b + ribavirin for genotypes 2 and 3
Trial: 16771948
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose pegylated interferon alpha-2b + ribavirin for genotypes 2 and 3
Trial: 16771948
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose pegylated interferon alpha-2b + ribavirin for genotype 1
Trial: 16771948
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose pegylated interferon alpha-2b + ribavirin for genotype 1
Trial: 16771948
Drug: Doses exceeding
RxNorm normalized name: Agents for dermatitis, excluding corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses exceeding the 1-2-5 threshold for genotype 1
Trial: 15596921
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further brain treatment (n = 46 patients)
Trial: 9848882
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol and 2.5 mg medroxyprogesterone (n=7)
Trial: 9848882
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol alone (n=8)
Trial: 8119527
Drug: Proximal duodenal
RxNorm normalized name: Sus scrofa duodenum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal duodenal distention (10, 20, 30 mL of air) during fasting
Trial: 8119527
Drug: Distal duodenal
RxNorm normalized name: Sus scrofa duodenum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal duodenal distention (10, 20, 30 mL of air) during fasting
Trial: 8119527
Drug: Proximal duodenal
RxNorm normalized name: Sus scrofa duodenum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal duodenal distention (10, 20, 30 mL of air) postprandially
Trial: 8119527
Drug: Distal duodenal
RxNorm normalized name: Sus scrofa duodenum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal duodenal distention (10, 20, 30 mL of air) postprandially
Trial: 2680866
Drug: alpha-interferon therapy
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alpha-interferon therapy (90 million units per m2 total dose over 12 weeks)
Trial: 336652
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg pentobarbital
Trial: 336652
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg methyprylon
Trial: 336652
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg glutethimide
Trial: 28661970
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection + postresuscitation care bundle
Trial: 26836793
Drug: Rivaroxaban (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (20 mg daily)
Trial: 19804594
Drug: Topical nicotinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nicotinamide (0.2% or 5%)